Dopamine Dependence of Offset Analgesia
抵消镇痛的多巴胺依赖性
基本信息
- 批准号:10390003
- 负责人:
- 金额:$ 4.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAmericanAnalgesicsBiological MarkersBrainClinicalClinical TrialsCoupledCross-Over TrialsDangerousnessDependenceDevelopmentDiagnosisDissociationDopamineDopamine ReceptorDopamine Uptake InhibitorsDouble-Blind MethodEconomic BurdenEnsureExerciseExhibitsFunctional Magnetic Resonance ImagingFutureHandHealthcare SystemsImageImpairmentIndividualInterventionKnowledgeLinkMaintenanceMediatingMethodsModalityModelingNeural PathwaysNociceptionNucleus AccumbensOpiate AddictionPainPain intensityParticipantPatientsPerceptionPharmacologyPlacebo ControlPlacebosPopulationPrognosisPsychophysicsRandomizedResearch PersonnelRewardsRitalinRoleScanningScienceSeriesSpecificityStatistical ModelsStimulusStressSystemTemperatureTestingTimeTrainingWorkbasechronic painchronic pain managementchronic pain patientclinically relevantcostdaily painexperienceexperimental studyheat stimulushedonicinsightmesolimbic systemmultimodal neuroimagingneurophysiologynovelopioid epidemicpain patientpatient populationresponsesocial
项目摘要
PROJECT SUMMARY
Chronic pain is ubiquitous, costly, and burdensome. Individuals with chronic pain suffer daily—the pain impairs
their ability to work, move, and live freely. On a societal level, chronic pain stresses both the healthcare system
and the economy. Despite its impact, there is no cure for chronic pain. The inability to properly treat chronic pain
has led to the current opioid epidemic. Although we are now beginning to understand the mechanisms underlying
chronic pain, we have few ways of assessing and probing these mechanisms. A chronic pain biomarker
mechanistically coupled to the circuitry responsible for inducing and maintaining chronic pain would help
researchers study and clinicians treat chronic pain.
Offset analgesia is a psychophysical phenomenon characterized by a transient, disproportionately large
decrease in pain following a slight reduction in noxious stimulus intensity. This phenomenon is both
mechanistically and clinically interesting. Mechanistically, it uncouples a noxious stimulus from pain qualia—two
often-conflated constructs. Clinically, it is blunted in patients with chronic pain, making it a biomarker for chronic
pain. Yet, we do not understand how offset analgesia occurs. By elucidating offset analgesia's mechanisms, we
will gain a greater understanding of the nociceptive-pain circuitry. Moreover, it would transmute offset analgesia
from a psychophysical correlate of chronic pain to a biomarker that provides neurophysiological insight.
This proposal aims to assess the dopamine dependence of offset analgesia. Although we do not know offset
analgesia's mechanisms, several lines of evidence suggest it may be dopaminergic. If the dopamine hypothesis
holds, then the core mechanisms responsible for chronic pain may also be responsible for mediating offset
analgesia. Aim 1 will attempt to generalize offset analgesia to other noxious stimuli since previous work has only
tested noxious heat stimuli. We will compare the offset analgesic response and dynamics between hot and cold
noxious stimuli. Establishing cold offset analgesia enables us to investigate its broader mechanisms by ensuring
our results are not specific to a single modality. Aim 2 will investigate the correlative role of nucleus accumbens
in offset analgesia. If the mesolimbic system is responsible for offset analgesia, its dynamics should capture the
temporal dissociation between the noxious stimulus (temperature) and pain ratings. Finally, in Aim 3, I will gain
experience in a clinical trial led by Dr. Apkarian that uses methylphenidate to perturb dopamine levels. An
increase in the offset analgesic response with methylphenidate relative to placebo would indicate dopamine
dependence. Understanding the dopamine dependence of offset analgesia is crucial to understanding its
underlying mechanisms and its use as a chronic pain biomarker.
项目概要
慢性疼痛无处不在,费用高昂且负担重,患有慢性疼痛的人每天都会遭受痛苦——疼痛会损害患者的健康。
在社会层面上,慢性疼痛给医疗保健系统带来压力。
尽管有其影响,但慢性疼痛无法治愈。
导致了当前阿片类药物的流行,尽管我们现在开始了解其背后的机制。
慢性疼痛,我们几乎没有方法来评估和探索这些慢性疼痛生物标志物。
机械耦合到负责诱发和维持慢性疼痛的电路将有助于
研究人员研究和治疗慢性疼痛。
偏置镇痛是一种心理物理现象,其特征是短暂的、不成比例的大
有害刺激强度轻微降低后疼痛减轻,这是两种现象。
从机制上和临床上来说,它把有害刺激与疼痛感受性分开——两种。
在临床上,它在慢性疼痛患者中被削弱,使其成为慢性疼痛的生物标志物。
然而,我们不了解偏置镇痛是如何发生的。通过阐明偏置镇痛的机制,我们。
将对伤害性疼痛回路有更深入的了解,此外,它将改变抵消镇痛作用。
从慢性疼痛的心理物理相关性到提供神经生理学见解的生物标志物。
该提案旨在评估抵消镇痛的多巴胺依赖性,尽管我们不知道抵消镇痛。
关于镇痛的机制,多项证据表明,如果多巴胺假说,它可能是多巴胺能的。
成立,那么造成慢性疼痛的核心机制也可能负责调节抵消
目标 1 将尝试将抵消镇痛推广到其他有害刺激,因为之前的工作仅
我们将比较热和冷之间的抵消镇痛反应和动力学。
建立冷补偿镇痛使我们能够通过确保其更广泛的机制。
我们的结果并不特定于单一模式。目标 2 将研究伏隔核的相关作用。
如果中脑边缘系统负责偏置镇痛,那么它的动态应该捕捉到
最后,在目标 3 中,我将获得有害刺激(温度)和疼痛等级之间的时间分离。
Apkarian 博士领导的一项使用哌醋甲酯扰乱多巴胺水平的临床试验的经验。
相对于安慰剂,哌醋甲酯抵消镇痛反应的增加表明多巴胺
了解抵消镇痛的多巴胺依赖性对于理解其依赖性至关重要。
潜在机制及其作为慢性疼痛生物标志物的用途。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Vigotsky其他文献
Andrew Vigotsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Vigotsky', 18)}}的其他基金
相似海外基金
Elucidating causal mechanisms of ethanol-induced analgesia in BXD recombinant inbred mouse lines
阐明 BXD 重组近交系小鼠乙醇诱导镇痛的因果机制
- 批准号:
10825737 - 财政年份:2023
- 资助金额:
$ 4.3万 - 项目类别:
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain
Cav3通道和可溶性环氧化物水解酶的单分子双重抑制剂治疗神经性疼痛的IND临床I期试验
- 批准号:
10760089 - 财政年份:2023
- 资助金额:
$ 4.3万 - 项目类别:
Resolvin receptor signaling in trigeminal sensory neurons
三叉神经感觉神经元中的 Resolvin 受体信号传导
- 批准号:
10738862 - 财政年份:2023
- 资助金额:
$ 4.3万 - 项目类别:
Characterizing the connectivity and molecular composition of opioid-sensitive neurons in the periaqueductal gray
导水管周围灰质阿片敏感神经元的连接和分子组成特征
- 批准号:
10605415 - 财政年份:2023
- 资助金额:
$ 4.3万 - 项目类别:
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
使用 T 型钙通道和可溶性环氧化物水解酶的活性 IND 双重抑制剂开发治疗酒精使用障碍的新型药物
- 批准号:
10815882 - 财政年份:2023
- 资助金额:
$ 4.3万 - 项目类别: